Seres Therapeutics - MCRB Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $6.67
  • Forecasted Upside: 523.05%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$1.07
▲ +0.09 (9.18%)

This chart shows the closing price for MCRB by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Seres Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MCRB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MCRB

Analyst Price Target is $6.67
▲ +523.05% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Seres Therapeutics in the last 3 months. The average price target is $6.67, with a high forecast of $10.00 and a low forecast of $4.00. The average price target represents a 523.05% upside from the last price of $1.07.

This chart shows the closing price for MCRB for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 3 contributing investment analysts is to moderate buy stock in Seres Therapeutics. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/21/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/21/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/20/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/18/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/16/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/15/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/14/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/14/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/7/2024OppenheimerReiterated RatingOutperform ➝ Market PerformLow
6/7/2024Canaccord Genuity GroupLower TargetBuy ➝ Buy$15.00 ➝ $10.00Low
5/9/2024OppenheimerLower TargetOutperform ➝ Outperform$5.00 ➝ $4.00Low
5/8/2024Chardan CapitalLower TargetBuy ➝ Buy$8.00 ➝ $6.00Low
3/6/2024OppenheimerLower TargetOutperform ➝ Outperform$9.00 ➝ $5.00Low
3/6/2024Chardan CapitalLower TargetBuy ➝ Buy$10.00 ➝ $8.00Low
1/16/2024OppenheimerLower TargetOutperform ➝ Outperform$10.00 ➝ $9.00Low
6/26/2023OppenheimerInitiated CoverageOutperform$12.00Low
4/28/2023Chardan CapitalLower Target$12.00 ➝ $10.00Low
4/21/2023JPMorgan Chase & Co.Initiated CoverageNeutral$7.00Low
3/21/2023Canaccord Genuity GroupBoost TargetBuy$11.00 ➝ $15.00Low
3/8/2023Chardan CapitalReiterated RatingBuy$12.00Low
3/8/2023Canaccord Genuity GroupLower TargetBuy$17.00 ➝ $11.00Low
3/8/2023HC WainwrightReiterated RatingBuy$25.00Low
2/8/2023HC WainwrightReiterated RatingBuy$25.00Low
12/8/2022Piper SandlerBoost Target$9.00 ➝ $13.00Low
9/7/2022Piper SandlerBoost TargetOverweight$7.00 ➝ $9.00Low
8/4/2022Chardan CapitalLower Target$16.00 ➝ $12.00Low
6/8/2022HC WainwrightReiterated RatingBuy$25.00High
6/8/2022Jefferies Financial GroupUpgradeBuyHigh
5/23/2022Piper SandlerLower TargetOverweight$32.00 ➝ $7.00High
5/5/2022HC WainwrightReiterated RatingBuy$25.00High
8/4/2021Chardan CapitalReiterated RatingBuy$16.00Medium
8/4/2021HC WainwrightReiterated RatingBuy$25.00Low
8/3/2021OppenheimerReiterated RatingOutperform$18.00 ➝ $16.00Medium
7/23/2021Chardan CapitalLower TargetBuy$30.00 ➝ $16.00Medium
7/23/2021HC WainwrightLower TargetBuy$46.00 ➝ $25.00High
7/23/2021The Goldman Sachs GroupDowngradeNeutral ➝ Sell$24.00 ➝ $7.00High
7/22/2021OppenheimerLower TargetOutperform$36.00 ➝ $18.00High
7/22/2021Piper SandlerLower TargetOverweight$40.00 ➝ $32.00High
7/9/2021Chardan CapitalInitiated CoverageBuy$30.00Low
7/1/2021Chardan CapitalReiterated RatingBuyLow
5/5/2021HC WainwrightBoost TargetPositive ➝ Buy$41.00 ➝ $46.00Medium
3/5/2021Chardan CapitalUpgradeNeutral ➝ Buy$27.50 ➝ $30.00High
3/2/2021OppenheimerReiterated RatingBuy$38.00High
12/23/2020JMP SecuritiesInitiated CoverageMarket PerformN/A
11/9/2020OppenheimerBoost TargetPositive ➝ Outperform$34.00 ➝ $38.00Low
11/9/2020Piper SandlerBoost TargetPositive ➝ Overweight$40.00 ➝ $49.00Medium
10/26/2020OppenheimerReiterated RatingOutperform$29.00 ➝ $34.00Low
9/18/2020Chardan CapitalDowngradeBuy ➝ Neutral$32.50 ➝ $27.50Medium
9/13/2020OppenheimerReiterated RatingBuy$29.00High
8/18/2020Piper SandlerInitiated CoverageOverweight$40.00Medium
8/11/2020HC WainwrightBoost TargetBuy$8.00 ➝ $41.00High
8/11/2020Jefferies Financial GroupUpgradeHold ➝ Buy$4.00 ➝ $29.00High
8/10/2020Chardan CapitalBoost TargetBuy$12.50 ➝ $32.50High
8/10/2020OppenheimerBoost TargetOutperform$7.00 ➝ $30.00Medium
7/28/2020OppenheimerReiterated RatingBuy$7.00High
6/25/2020Chardan CapitalReiterated RatingBuy ➝ Market Perform$12.50Medium
3/31/2020OppenheimerLower TargetOutperform$8.00 ➝ $7.00High
3/23/2020HC WainwrightReiterated RatingBuy$8.00High
11/21/2019HC WainwrightReiterated RatingBuy$8.00Low
11/4/2019CowenReiterated RatingBuyHigh
9/19/2019Chardan CapitalReiterated RatingBuyLow
(Data available from 7/14/2019 forward)

News Sentiment Rating

0.20 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/17/2023
  • 3 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/16/2024
  • 2 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/15/2024
  • 6 very positive mentions
  • 16 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/16/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/15/2024
  • 2 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
5/15/2024
  • 0 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
6/14/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/14/2024

Current Sentiment

  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Positive

Seres Therapeutics logo
Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $1.07
Low: $0.98
High: $1.10

50 Day Range

MA: $0.87
Low: $0.61
High: $1.19

52 Week Range

Now: $1.07
Low: $0.54
High: $5.29

Volume

2,888,422 shs

Average Volume

3,136,283 shs

Market Capitalization

$162.05 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.98

Frequently Asked Questions

What sell-side analysts currently cover shares of Seres Therapeutics?

The following Wall Street analysts have issued research reports on Seres Therapeutics in the last twelve months: Canaccord Genuity Group Inc., Chardan Capital, Oppenheimer Holdings Inc., and StockNews.com.
View the latest analyst ratings for MCRB.

What is the current price target for Seres Therapeutics?

3 Wall Street analysts have set twelve-month price targets for Seres Therapeutics in the last year. Their average twelve-month price target is $6.67, suggesting a possible upside of 523.1%. Canaccord Genuity Group Inc. has the highest price target set, predicting MCRB will reach $10.00 in the next twelve months. Oppenheimer Holdings Inc. has the lowest price target set, forecasting a price of $4.00 for Seres Therapeutics in the next year.
View the latest price targets for MCRB.

What is the current consensus analyst rating for Seres Therapeutics?

Seres Therapeutics currently has 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for MCRB.

What other companies compete with Seres Therapeutics?

Other companies that are similar to Seres Therapeutics include FibroGen, Nektar Therapeutics, ALX Oncology, Alumis and Editas Medicine. Learn More about companies similar to Seres Therapeutics.

How do I contact Seres Therapeutics' investor relations team?

Seres Therapeutics' physical mailing address is 200 SIDNEY STREET - 4TH FLOOR, CAMBRIDGE MA, 02139. The biotechnology company's listed phone number is (617) 945-9626 and its investor relations email address is [email protected]. The official website for Seres Therapeutics is www.serestherapeutics.com. Learn More about contacing Seres Therapeutics investor relations.